Ependymoma – Pipeline Review, H2 2011 by GlobalMarketsDirect

VIEWS: 6 PAGES: 54

More Info
									Ependymoma – Pipeline Review, H2 2011




                      Ependymoma – Pipeline Review, H2 2011


                                                                                          Reference Code: GMDHC1602IDB
                                                                                          Publication Date: December 2011




Ependymoma – Pipeline Review, H2 2011                                                     GMDHC1602IDB / Pub December 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Ependymoma – Pipeline Review, H2 2011




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 5
    List of Figures ................................................................................................................................................................................ 5
Introduction......................................................................................................................................................................................... 6
    Global Markets Direct Report Coverage ........................................................................................................................................ 6
Ependymoma Overview ..................................................................................................................................................................... 7
Therapeutics Development................................................................................................................................................................. 8
    An Overview of Pipeline Products for Ependymoma ..................................................................................................................... 8
Ependymoma Therapeutics under Development by Companies...................................................................................................... 10
Ependymoma Therapeutics under Investigation by Universities/Institutes ....................................................................................... 11
Late Stage Products ......................................................................................................................................................................... 13
    Comparative Analysis .................................................................................................................................................................. 13
Mid Clinical Stage Products.............................................................................................................................................................. 14
    Comparative Analysis .................................................................................................................................................................. 14
Early Clinical Stage Products ........................................................................................................................................................... 15
    Comparative Analysis .................................................................................................................................................................. 15
Ependymoma Therapeutics – Products under Development by Companies.................................................................................... 16
Ependymoma Therapeutics – Products under Investigation by Universities/Institutes ..................................................................... 17
Companies Involved in Ependymoma Therapeutics Development .................................................................................................. 18
    Eli Lilly and Company .................................................................................................................................................................. 18
    OSI Pharmaceuticals, Inc. ........................................................................................................................................................... 19
Ependymoma – Therapeutics Assessment ...................................................................................................................................... 20
    Assessment by Monotherapy Products ....................................................................................................................................... 20
    Assessment by Combination Products ........................................................................................................................................ 21
    Assessment by Route of Administration ...................................................................................................................................... 22
    Assessment by Molecule Type .................................................................................................................................................... 24
Drug Profiles..................................................................................................................................................................................... 26
    Temozolomide + Lapatinib - Drug Profile .................................................................................................................................... 26
         Product Description................................................................................................................................................................. 26
         Mechanism of Action ............................................................................................................................................................... 26
         R&D Progress ......................................................................................................................................................................... 26
    Alimta - Drug Profile .................................................................................................................................................................... 27
         Product Description................................................................................................................................................................. 27
         Mechanism of Action ............................................................................................................................................................... 27
         R&D Progress ......................................................................................................................................................................... 27
    Methotrexate - Drug Profile.......................................................................................................................................................... 29
         Product Description................................................................................................................................................................. 29
         Mechanism of Action ............................................................................................................................................................... 29
         R&D Progress ......................................................................................................................................................................... 29
    Temozolomide + Etoposide - Drug Profile ................................................................................................................................... 30
         Product Description................................................................................................................................................................. 30
         Mechanism of Action ............................................................................................................................................................... 30



Ependymoma – Pipeline Review, H2 2011                                                                                                     GMDHC1602IDB / Pub December 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Ependymoma – Pipeline Review, H2 2011



        R&D Progress ......................................................................................................................................................................... 30
    GW572016 - Drug Profile ............................................................................................................................................................ 31
        Product Description................................................................................................................................................................. 31
        Mechanism of Action ............................................................................................................................................................... 31
        R&D Progress ......................................................................................................................................................................... 31
    Bevacizumab + Camptosar - Drug Profile ................................................................................................................................... 32
        Product Description................................................................................................................................................................. 32
        Mechanism of Action ............................................................................................................................................................... 32
        R&D Progress ......................................................................................................................................................................... 32
    Bevacizumab + Lapatinib - Drug Profile ...................................................................................................................................... 34
        Product Description................................................................................................................................................................. 34
        Mechanism of Action ............................................................................................................................................................... 34
        R&D Progress ......................................................................................................................................................................... 34
    Torisel - Drug Profile.................................................................................................................................................................... 35
        Product Description................................................................................................................................................................. 35
        Mechanism of Action ............................................................................................................................................................... 35
        R&D Progress ......................................................................................................................................................................... 35
    Cisplatin + Etoposide - Drug Profile ............................................................................................................................................. 36
        Product Description................................................................................................................................................................. 36
        Mechanism of Action ............................................................................................................................................................... 36
        R&D Progress ......................................................................................................................................................................... 36
    Cisplatin + Etoposide - Drug Profile ............................................................................................................................................. 37
        Product Description................................................................................................................................................................. 37
        Mechanism of Action ............................................................................................................................................................... 37
        R&D Progress ......................................................................................................................................................................... 37
    Verteporfin - Drug Profile ............................................................................................................................................................. 38
        Product Description................................................................................................................................................................. 38
        Mechanism of Action ............................................................................................................................................................... 38
        R&D Progres
								
To top